Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension

Chest

Volumn 124, Issue 4, 2003, Pages 1612-1615

  Kim, Nick H ^a   Channick, Richard N ^a   Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epoprostenol; Flolan; Pulmonary hypertension

Indexed keywords

BOSENTAN; DILTIAZEM; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEART CATHETERIZATION; HEMODYNAMIC MONITORING; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; OUTPATIENT DEPARTMENT; PAIN; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WORLD HEALTH ORGANIZATION;

EID: 0142074234     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.4.1612     Document Type: Article

References (17)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
2. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425-434
3. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
4. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788
5. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111-117
6. Gaine S. Pulmonary hypertension. JAMA 2000; 284:3160-3168
7. Falk A, Lookstein RA, Mitty HA. Flolan infusion interruption: a lethal complication during venous access. J Vasc Interv Radiol 2001; 12:667-668
8. Rich S, ed. Executive summary of the World Symposium on Primary Pulmonary Hypertension 1998. Available at: http://wwv.who.int/ncd/cvd/pph.html. Accessed on October 9, 2001
9. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-277
10. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102:2720-2725
11. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002; 26:194-201
12. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 1999; 99:3266-3271
13. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739
14. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569
15. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
16. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403
17. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-522 1615